Kura Oncology and Kyowa Kirin announce FDA acceptance and Priority Review of New Drug Application for ziftomenib in adults with relapsed or refractory NPM1-mutant AML. News release. Kura Oncology.

The NPM1 mutation affects about 30% of all AML patients. In almost half of those patients, relapse or resistance to standard treatments occurs within a year of treatment.

The Advertising Research Foundation (ARF) today announced the release of the ARF Handbook for Using AI in Advertising Research (2025), a comprehensive guide that explores how artificial ...

ARF Hamptons Logo Supporters at Pet Celebration Day 2025 (Photo credit: Lisa Tamburini) Ellen Scarborough, Kim Nichols (Photo credit. Tuesday, 02 January 2024 12:17 GMT.

Led by Ryan Flynn, MD, PhD, assistant professor of stem cell and regenerative biology at Harvard Medical School (HMS), the study identified one RNA-binding protein on the cell surface, NPM1, as a ...

Targeting the NPM1 protein. AML, a rapidly progressive blood cancer, has been difficult to target therapeutically because many of its driving pathways are also essential for non-cancerous cells, ...

This is not insignificant; if your ARF is worth €100,000, it will cost you between €1,000 and €1,500 a year, increasing to between €5,000 and €7,500 for an ARF valued at €500,000.

Ziftomenib targets relapsed/refractory AML with NPM1 mutations, a condition with high relapse rates and poor survival outcomes. The drug has received breakthrough therapy, fast track, and orphan drug ...

JP Morgan raised Syndax's price target to $41, citing strong early Revuforj sales and physician confidence in its use for acute leukemias and NPM1 AML.

p14 ARF networking is key to tumor suppression. ... p14ARF forms meso-scale assemblies upon phase separation with NPM1. Nature Communications, 2024; 15 (1) DOI: 10.1038/s41467-024-53904-z; ...

Kura is on track to complete the registration-directed trial of ziftomenib in R/R NPM1-mutant AML by mid-2024. Ziftomenib is also being evaluated in combination with current standards of care ...

Overall, the current analysis included the 737 patients with NPM1-mutated AML, 348 from AML17 and 389 from AML19, who were in complete remission after two courses of treatment and had an MRD ...